Non-myeloablative lymphodepleting chemotherapy-Centre Hospitalier Universitaire Vaudois-melanoma-sarcoma

Non-myeloablative lymphodepleting chemotherapy-Centre Hospitalier Universitaire Vaudois-melanoma-sarcoma refers to the specific preparatory chemotherapy regimen used in a Phase I clinical trial (NCT06889766) at the Centre Hospitalier Universitaire Vaudois (CHUV). This conditioning treatment consists of fludarabine (30 mg/m² for 4 days) and cyclophosphamide (2400 mg/m² for 2 days, potentially reduced to 1800 mg/m²) administered intravenously prior to the infusion of LauT-1, an autologous T-cell product. LauT-1 consists of T-cells genetically modified to express a high-affinity T-cell receptor (TCR) targeting the NY-ESO-1 antigen. The lymphodepleting regimen is designed to eliminate the patient's existing lymphocytes, thereby creating a niche that facilitates the expansion and persistence of the engineered T-cells in patients with NY-ESO-1 positive advanced melanoma and sarcoma.

Other names

Non-myeloablative lymphodepleting chemotherapyNMA lymphodepletionFlu/Cy conditioningfludarabine + cyclophosphamide